Leben Care offers Artificial Intelligence-based diagnostic and screening solutions, primarily known for automated, fast and affordable retinal screening.
Leben Care Technologies Pte Ltd, the Singapore-based retinal diagnostic startup, has raised angel funding from Inflection Point (IP) Ventures to fight avoidable blindness. The fresh capital will be used by the company to upgrade its product and sales and marketing team.
Founded by Nitin Srivastava, Theenathayalan Parthasarathy and Imran Akthar in 2016, Leben Care offers Artificial Intelligence-based diagnostic and screening solutions, primarily known for automated, fast and affordable retinal screening.
Leben Care’s flagship product, Netra.AI, enables automated analysis of retina image using AI algorithms for avoiding blindness. The company helps in conducting basic screening with minimal intervention from specialists.
Currently, Leben Care has a presence in India, Japan, Singapore, Africa and Australia through partnerships with distributors and ophthalmology centers.
Nitin Srivastava, Co-Founder and Chief Executive Officer, Leben care, said, “We are on a mission to fight avoidable blindness using AI and hope to make this technology available to millions who struggle to get access to basic screening.”
“Our platform Netra.ai is intended to be the go-to place for all ophthalmology related AI solutions,” he added.
Mitesh Shah, Co-Founder of IP Ventures, stated, “Leben Care has a competent team and some great strategic partnerships. We are very excited to partner with them.”